edwards
Breaking into the oncology market
March 10, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Cancer, NSCLC, edwards, gilotrif, oncology
In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
